• Revenue grew 5.8% year-over-year to A$1.55 million
• Gross profit margin declined to 54.3% from 59.7% in prior year
• Net loss widened to A$3.84 million from A$3.44 million

Universal Biosensors, Inc. reported its financial results for the first quarter ended March 31, 2025. The company's revenue grew 5.8% year-over-year to A$1.55 million, driven by increased product sales. However, the gross profit margin declined to 54.3% from 59.7% in the prior year quarter, primarily due to higher cost of goods sold. Operating expenses increased, with research and development costs rising to A$795,503 and selling, general and administrative expenses reaching A$4.36 million. As a result, the company reported a net loss of A$3.84 million, widening from a net loss of A$3.44 million in the same period of 2024. The company's cash and cash equivalents stood at A$4.92 million as of March 31, 2025, down from A$8.90 million at the start of the quarter, as the company continued to use cash to fund its operations. Management is exploring options to raise additional capital to support the company's growth plans and ensure its ability to continue as a going concern.